GlobeNewswire: Amunix Pharmaceuticals, Inc. Contains the last 10 of 19 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:58:35ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/10/07/2310495/0/en/Amunix-Presents-Preclinical-Data-on-Its-XPAT-T-Cell-Engager-Platform-at-the-AACR-NCI-EORTC-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html?f=22&fvtc=4&fvtv=34906Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics2021-10-07T13:00:00Z<![CDATA[AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors.]]>https://www.globenewswire.com/news-release/2021/06/23/2251610/0/en/Amunix-Appoints-Industry-Veteran-Frank-Watanabe-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=34906Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors2021-06-23T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engager and cytokine therapies for patients with cancer, today announced that it has expanded its board of directors with the appointment of Frank Watanabe, CEO of Arcutis and a biopharmaceutical executive with extensive leadership, strategy, operations and financing experience.]]>https://www.globenewswire.com/news-release/2021/05/13/2228949/0/en/Amunix-Expands-its-Board-of-Directors-with-the-Appointment-of-Industry-Veteran-Ciara-Kennedy-Ph-D-M-B-A.html?f=22&fvtc=4&fvtv=34906Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.2021-05-13T11:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, today announced the appointment of Ciara Kennedy, Ph.D., M.B.A. to its board of directors. Dr. Kennedy brings to Amunix a wealth of strategic and operational experience across multiple therapeutic areas and stages of development in the biopharmaceutical industry.]]>https://www.globenewswire.com/news-release/2021/04/12/2208186/0/en/Amunix-Presents-Preclinical-Data-at-American-Academy-of-Cancer-Research-AACR-Annual-Meeting-from-Lead-Program-AMX-818-Demonstrating-Robust-Efficacy-in-HER2-Tumor-Models-and-Enhance.html?f=22&fvtc=4&fvtv=34906Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety2021-04-12T12:00:00Z<![CDATA[AMX-818 is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated T cell engager) platform designed to improve the toxicity profile of T cell engagers for the treatment of HER2-expressing solid tumors]]>https://www.globenewswire.com/news-release/2021/03/04/2187044/0/en/Amunix-Raises-117-Million-Series-B-Financing-to-Fund-its-Oncology-Pipeline.html?f=22&fvtc=4&fvtv=34906Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline2021-03-04T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced that it has raised $117 million Series B financing. The funding round was led by Viking Global Investors with participation from a premier syndicate of funds, including new investors Bain Capital Life Sciences, BlackRock, Franklin Templeton, Janus Henderson Investors, ArrowMark Partners, Avidity Partners, certain funds managed by Clough Capital Partners, and CaaS Capital Management. Also participating in the round were existing investors Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, and Polaris Partners.]]>https://www.globenewswire.com/news-release/2021/01/26/2164130/0/en/Amunix-Announces-the-Appointment-of-Healthcare-Investment-Banking-Veteran-Zeeshan-Merchant-as-Chief-Financial-Officer-and-Trisha-Millican-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=34906Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors2021-01-26T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors.]]>https://www.globenewswire.com/news-release/2020/12/09/2142300/0/en/Amunix-Presents-Preclinical-Data-on-AMX-818-a-Protease-Activated-HER2-Targeted-T-Cell-Engager-Prodrug-at-SABCS-2020.html?f=22&fvtc=4&fvtv=34906Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 20202020-12-09T14:00:00Z<![CDATA[– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –]]>https://www.globenewswire.com/news-release/2020/09/17/2095091/0/en/Amunix-to-Present-Preclinical-Data-on-Protease-Activated-HER2-and-EGFR-Targeted-T-Cell-Engagers-at-ESMO-Virtual-Congress-2020.html?f=22&fvtc=4&fvtv=34906Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 20202020-09-17T11:00:00Z<![CDATA[– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –]]>https://www.globenewswire.com/news-release/2020/06/22/2051294/0/en/Amunix-to-Present-Preclinical-Data-on-HER2-and-EGFR-Targeted-T-Cell-Engagers-at-AACR-Virtual-Annual-Meeting-II.html?f=22&fvtc=4&fvtv=34906Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II2020-06-22T13:00:00Z<![CDATA[Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors]]>https://www.globenewswire.com/news-release/2020/05/27/2039211/0/en/Amunix-Appoints-Anne-Keane-as-Senior-Vice-President-of-Regulatory-and-Quality.html?f=22&fvtc=4&fvtv=34906Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality2020-05-27T11:00:00Z<![CDATA[MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.]]>